SK287533B6 - Liečivo na liečenie viacpočetných rezistentných nádorov alebo na inhibíciu angiogenézy a metastáz - Google Patents

Liečivo na liečenie viacpočetných rezistentných nádorov alebo na inhibíciu angiogenézy a metastáz Download PDF

Info

Publication number
SK287533B6
SK287533B6 SK407-2002A SK4072002A SK287533B6 SK 287533 B6 SK287533 B6 SK 287533B6 SK 4072002 A SK4072002 A SK 4072002A SK 287533 B6 SK287533 B6 SK 287533B6
Authority
SK
Slovakia
Prior art keywords
acid
glyoxylamide
indol
pyridin
group
Prior art date
Application number
SK407-2002A
Other languages
English (en)
Slovak (sk)
Other versions
SK4072002A3 (en
Inventor
Bernd Nickel
Thomas Klenner
Gerald Bacher
Thomas Beckers
Peter Emig
J�Rgen Engel
Erik Bruyneel
G�Nter Kamp
Kirsten Peters
Original Assignee
Ziopharm Oncology, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19946301A external-priority patent/DE19946301A1/de
Application filed by Ziopharm Oncology, Inc. filed Critical Ziopharm Oncology, Inc.
Publication of SK4072002A3 publication Critical patent/SK4072002A3/sk
Publication of SK287533B6 publication Critical patent/SK287533B6/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
SK407-2002A 1999-09-28 2000-09-26 Liečivo na liečenie viacpočetných rezistentných nádorov alebo na inhibíciu angiogenézy a metastáz SK287533B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19946301A DE19946301A1 (de) 1998-04-02 1999-09-28 Indolyl-3-glyoxylsäure-Derivate mit therapeutisch wertvollen Eigenschaften
PCT/EP2000/009390 WO2001022954A2 (de) 1999-09-28 2000-09-26 Indolyl-3-glyoxylsäurederivate als antitumormittel

Publications (2)

Publication Number Publication Date
SK4072002A3 SK4072002A3 (en) 2003-11-04
SK287533B6 true SK287533B6 (sk) 2011-01-04

Family

ID=7923485

Family Applications (1)

Application Number Title Priority Date Filing Date
SK407-2002A SK287533B6 (sk) 1999-09-28 2000-09-26 Liečivo na liečenie viacpočetných rezistentných nádorov alebo na inhibíciu angiogenézy a metastáz

Country Status (32)

Country Link
EP (1) EP1218006B1 (zh)
JP (1) JP2003510274A (zh)
KR (1) KR100759242B1 (zh)
CN (1) CN1301712C (zh)
AR (1) AR025885A1 (zh)
AT (1) ATE459356T1 (zh)
AU (1) AU783436B2 (zh)
BG (1) BG106639A (zh)
BR (1) BR0014378A (zh)
CA (1) CA2386069C (zh)
CZ (1) CZ303246B6 (zh)
DE (1) DE50015879D1 (zh)
DZ (1) DZ3196A1 (zh)
EE (1) EE200200169A (zh)
ES (1) ES2342042T3 (zh)
GE (1) GEP20043250B (zh)
HK (1) HK1048941B (zh)
HR (1) HRP20020369A2 (zh)
HU (1) HUP0202788A3 (zh)
IL (2) IL148670A0 (zh)
IS (1) IS6319A (zh)
MX (1) MXPA02002824A (zh)
NO (1) NO322614B1 (zh)
NZ (1) NZ517988A (zh)
PL (1) PL199576B1 (zh)
RS (1) RS51302B (zh)
RU (1) RU2282444C2 (zh)
SK (1) SK287533B6 (zh)
TW (1) TWI269654B (zh)
UA (1) UA75872C2 (zh)
WO (1) WO2001022954A2 (zh)
ZA (1) ZA200202556B (zh)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19962300A1 (de) * 1999-12-23 2001-06-28 Asta Medica Ag Substituierte N-Benzyl-Indol-3-yl-glyoxylsäure-Derivate mit Antitumorwirkung
IL152682A0 (en) 2000-05-31 2003-06-24 Astrazeneca Ab Indole derivatives with vascular damaging activity
DE10037310A1 (de) 2000-07-28 2002-02-07 Asta Medica Ag Neue Indolderivate und deren Verwendung als Arzneimittel
EP1484329A1 (de) * 2003-06-06 2004-12-08 Zentaris GmbH Indolderivate mit Apoptose induzierender Wirkung
EP1595878A1 (de) * 2004-05-15 2005-11-16 Zentaris GmbH Indolderivate mit Apoptose induzierender Wirkung
JP4878285B2 (ja) * 2003-06-05 2012-02-15 エテルナ ツェンタリス ゲゼルシャフト ミット ベシュレンクテル ハフツング アポトーシス誘発作用を有するインドール誘導体
US20050124623A1 (en) 2003-11-26 2005-06-09 Bender John A. Diazaindole-dicarbonyl-piperazinyl antiviral agents
WO2005115992A1 (en) * 2004-05-23 2005-12-08 Housey Pharmaceuticals, Inc. Theramutein modulators
ES2424255T3 (es) * 2004-11-08 2013-09-30 Baxter International Inc. Composiciones particuladas de inhibidores de tubulina
US20060100432A1 (en) 2004-11-09 2006-05-11 Matiskella John D Crystalline materials of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
WO2006073973A2 (en) 2004-12-31 2006-07-13 Reddy Us Therapeutics, Inc. Novel benzylamine derivatives as cetp inhibitors
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
US7851476B2 (en) 2005-12-14 2010-12-14 Bristol-Myers Squibb Company Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-YL)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-YL]-1,2-dioxoethyl]-piperazine
US7807671B2 (en) 2006-04-25 2010-10-05 Bristol-Myers Squibb Company Diketo-piperazine and piperidine derivatives as antiviral agents
AU2007325797B2 (en) * 2006-11-28 2014-03-13 Ziopharm Oncology, Inc. Use of indolyl-3-glyoxylic acid derivatives including indibulin, alone or in combination with further agents for treating cancer
CA2845284C (en) 2011-08-18 2018-03-06 Dr. Reddy's Laboratories Ltd. Substituted heterocyclic amine compounds as cholesteryl ester-transfer protein (cetp) inhibitors
AU2012313971B2 (en) 2011-09-27 2016-09-29 Dr. Reddy's Laboratories, Ltd. 5 - benzylaminomethyl - 6 - aminopyrazolo [3, 4 -b] pyridine derivatives as cholesteryl ester -transfer protein (CETP) inhibitors useful for the treatment of atherosclerosis
WO2014089177A2 (en) 2012-12-04 2014-06-12 Massachusetts Institute Of Technology Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
WO2014144715A1 (en) 2013-03-15 2014-09-18 Memorial Sloan-Kettering Cancer Center Hsp90-targeted cardiac imaging and therapy
WO2017197045A1 (en) 2016-05-11 2017-11-16 Movassaghi Mohammad Convergent and enantioselective total synthesis of communesin analogs
US11932650B2 (en) 2017-05-11 2024-03-19 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
CN109111501B (zh) * 2017-06-23 2022-04-22 首都医科大学 脂肪氨基酸修饰的吲哚乙醇衍生物, 其合成，活性和应用
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
WO2020247054A1 (en) 2019-06-05 2020-12-10 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
WO2022182415A1 (en) 2021-02-24 2022-09-01 Massachusetts Institute Of Technology Himastatin derivatives, and processes of preparation thereof, and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
CA2126217A1 (en) * 1992-10-20 1994-04-28 Katsuhiro Shibayama Agent for suppressing infiltration of eosinophilis
DE19636150A1 (de) * 1996-09-06 1998-03-12 Asta Medica Ag N-substituierte Indol-3-glyoxylamide mit antiasthmatischer, antiallergischer und immunsuppressiver/immunmodulierender Wirkung
WO1998045431A1 (fr) 1997-04-08 1998-10-15 Banyu Pharmaceutical Co., Ltd. Gene associe a la metastase cancereuse
GEP20032920B (en) * 1998-02-25 2003-03-25 Genetics Inst Inhibitors of Phospholipase Enzymes
JP2004500308A (ja) * 1998-03-12 2004-01-08 ノボ　ノルディスク　アクティーゼルスカブ プロテインチロシンホスアターゼのモジュレーター
DE19814838C2 (de) 1998-04-02 2001-01-18 Asta Medica Ag Indolyl-3-glyoxylsäure-Derivate mit Antitumorwirkung
TR200003130T2 (tr) * 1998-04-28 2001-01-22 Arzneimittelwerk Dresden Gmbh Yeni hidroksiindoller, bunların fosfodiesteraz 4 inhibitörleri olarak kullanımları ve hazırlanmaları için işlemler
JP2000239252A (ja) * 1999-02-16 2000-09-05 Mitsubishi Chemicals Corp インドール誘導体
AU4834200A (en) * 1999-05-10 2000-11-21 Protarga, Inc. Fatty acid-n-substituted indol-3-glyoxyl-amide compositions and uses thereof

Also Published As

Publication number Publication date
YU22702A (sh) 2004-12-31
CZ20021005A3 (cs) 2004-01-14
AR025885A1 (es) 2002-12-18
ES2342042T3 (es) 2010-07-01
EP1218006A2 (de) 2002-07-03
EP1218006B1 (de) 2010-03-03
AU7782900A (en) 2001-04-30
ZA200202556B (en) 2003-08-27
NO20021367L (no) 2002-05-22
AU783436B2 (en) 2005-10-27
HUP0202788A3 (en) 2003-02-28
UA75872C2 (en) 2006-06-15
BR0014378A (pt) 2003-07-29
CN1376064A (zh) 2002-10-23
WO2001022954A2 (de) 2001-04-05
CA2386069C (en) 2012-08-14
PL199576B1 (pl) 2008-10-31
RU2282444C2 (ru) 2006-08-27
WO2001022954A3 (de) 2002-03-28
HRP20020369A2 (en) 2004-12-31
CN1301712C (zh) 2007-02-28
IL148670A0 (en) 2002-09-12
TWI269654B (en) 2007-01-01
BG106639A (bg) 2002-12-29
HK1048941B (zh) 2007-09-21
NO322614B1 (no) 2006-11-06
EE200200169A (et) 2003-04-15
ATE459356T1 (de) 2010-03-15
CA2386069A1 (en) 2001-04-05
KR100759242B1 (ko) 2007-09-18
SK4072002A3 (en) 2003-11-04
IL148670A (en) 2009-09-01
PL364811A1 (en) 2004-12-13
MXPA02002824A (es) 2003-07-21
HUP0202788A2 (hu) 2003-01-28
NZ517988A (en) 2004-10-29
NO20021367D0 (no) 2002-03-19
JP2003510274A (ja) 2003-03-18
DE50015879D1 (de) 2010-04-15
RS51302B (sr) 2010-12-31
KR20030019295A (ko) 2003-03-06
CZ303246B6 (cs) 2012-06-20
DZ3196A1 (fr) 2001-04-05
IS6319A (is) 2002-03-21
HK1048941A1 (en) 2003-04-25
GEP20043250B (en) 2004-06-25

Similar Documents

Publication Publication Date Title
SK287533B6 (sk) Liečivo na liečenie viacpočetných rezistentných nádorov alebo na inhibíciu angiogenézy a metastáz
US12102620B2 (en) Combination therapy for the treatment of mastocytosis
US20080057124A1 (en) Indolyl-3-glyoxylic acid derivatives having therapeutically valuable properties
US20080234230A1 (en) Pharmaceutical Composition for Regulation of Pancreatic Juice Secretion Comprising a LPA Receptor Modulator
WO2003074045A1 (fr) Agent antitumoral comprenant une combinaison d'un compose heterocyclique contenant un sulfamide et d'un inhibiteur d'angiogenese
EP3493848A1 (en) Heterocyclic diamidines
AU2015266552A1 (en) Pharmaceutical composition comprising pyrazine carboxamide compound as active ingredient
US20130345231A1 (en) Anticancer therapeutic agents
US7358236B1 (en) Control of acute hypertension and cardiotoxicity in patients treated with vascular targeting agents
US20040138207A1 (en) Antitumor agents
AU2002336130B2 (en) Pyridin-2-YL-Methlyamine derivatives for treating opioid dependence
EP1532978A1 (en) Remedy for urinary frequency and urinary incontinence
US20040048776A1 (en) Medicament for preventive and therapeutic treatment of fibrosis
JP2000086518A (ja) 血管攣縮の予防・治療剤
ITMI962241A1 (it) Uso di derivati tetraidro-beta-carbolinici come agenti antimetastatici
WO2014089450A1 (en) Specific inhibitors of cdk3
WO2003089426A1 (fr) Medicament prophylactique ou therapeutique contre le syndrome de coagulation intravasculaire disseminee

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of maintenance fees

Effective date: 20140926